Trial Profile
A 54 week, extension to the double-blind, multicenter, multifactorial, placeco-controlled, study to evaluate the efficacy and safety of valsartan (160 mg and 320 mg) and amlodipine (10 mg) combined and alone in hypertensive patients.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Oct 2023
Price :
$35
*
At a glance
- Drugs Amlodipine (Primary) ; Valsartan (Primary)
- Indications Hypertension
- Focus Adverse reactions
- 06 Nov 2005 New trial record.